Breast Cancer | Specialty

Dr. Mittendorf on Peptide Vaccines for Breast Cancer

July 19th 2013

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Suzanne A. W. Fuqua, PhD, on the Androgen Receptor

July 18th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the androgen receptor in breast cancer.

Dr. Seidman Discusses Less Lymph Node Surgery

July 11th 2013

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Retrospective Analysis Confirms Poor Prognosis for Breast Cancer Patients With BRCA1 Mutations

July 11th 2013

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

July 8th 2013

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Hypofractionation Emerges as Standard, but Not Yet for Every Patient

July 8th 2013

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivors⎯protocols that could greatly improve collective outcome.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

June 25th 2013

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.

Ellen Matloff on the Supreme Court Gene Patenting Decision

June 25th 2013

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Amount of HER2 Expression Associated With Response to T-DM1 in HER2-Positive Metastatic Breast Cancer

June 21st 2013

Women with the highest expression of HER2 had the most benefit from T-DM1, while the presence of PIK3CA mutations had no effect on response to T-DM1 but did interfere with response to capecitabine/lapatinib.

Dr. Hudis on the CALGB 40601 Study in Breast Cancer

June 20th 2013

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. O'Shaughnessy on Eribulin in Metastatic Breast Cancer

June 14th 2013

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.

Dr. Aft on Disseminating Tumor Cells and Prognosis

June 14th 2013

Rebecca L. Aft, MD, PhD, discusses the identification of patients with breast cancer at high risk of recurrent disease development by detection of HER2-positive disseminated tumor cells in bone marrow of patients with HER2-negative tumors.

Supreme Court Limits Ability to Patent Genes in Landmark Decision

June 13th 2013

After years of varying decisions by lower courts regarding the patents held on a test for genetic mutations associated with breast cancer, the US Supreme Court has ruled that a segment of DNA in isolation is a natural product and not eligible for patent protection.

Leading Oncologists Analyze Impact of New HER2 Research on Clinical Practice

June 11th 2013

Although recent findings suggest some patients with HER2-negative breast cancer would benefit from therapies directed against overexpression of the protein, two leading oncologists do not see an immediate impact on clinical practice as further validation is needed.

Dr. Lehman Discusses the Use of Breast MRI

June 10th 2013

Constance D. Lehman, MD, PhD, Vice Chair, Radiology Department, University of Washington School of Medicine, Medical Director, Imaging, Seattle Cancer Care Alliance, discusses the use of breast MRI.

Conclusion and Final Thoughts on Managing Breast Cancer

June 9th 2013

Personalized Medicine in Triple-Negative Breast Cancer

June 9th 2013

Case Study: Metastatic Triple-Negative Breast Cancer

June 9th 2013